Loading...

Home
ETF
GALT

GALT

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

GALT News

Galectin Therapeutics Under Investigation, Stock Plummets 28.9%

Jan 22 2026PRnewswire

Galectin Therapeutics Under Investigation, Stock Plummets 28.9%

Jan 15 2026PRnewswire

Galectin Therapeutics Faces 28.9% Stock Drop Following FDA Response on Belapectin Trial

Jan 08 2026PRnewswire

Galectin Therapeutics Faces Securities Fraud Investigation as Stock Plummets 28.9%

Jan 06 2026Globenewswire

Galectin Therapeutics Faces 28.9% Stock Drop Following FDA Response on Belapectin Trial

Dec 30 2025Globenewswire

Galectin Therapeutics Shares Plunge 28.9% Following FDA Response on Belapectin Development

Dec 30 2025Businesswire

Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway

Dec 26 2025NASDAQ.COM

Galectin Therapeutics Receives FDA Feedback to Advance Belapectin Development

Dec 22 2025NASDAQ.COM

Galectin Therapeutics (GALT) Price Target Raised by 83.33% to $11.22

Dec 21 2025NASDAQ.COM

Galectin Therapeutics Receives FDA Feedback to Advance Belapectin Development

Dec 19 2025Globenewswire

Galectin Therapeutics Receives FDA Feedback to Advance Belapectin Development

Dec 19 2025Newsfilter

Galectin Experiences Decline Following Update on MASH Candidate Belapectin and New $10M Credit Line

Dec 19 2025SeekingAlpha

Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers

Dec 19 2025NASDAQ.COM

Stitch Fix Reports Q4 Earnings, Alongside Transocean, MBX Biosciences, and Other Major Stocks Declining in Thursday's Pre-Market Trading

Sep 25 2025Benzinga

Galectin Therapeutics Inc. (GALT) Sees 7.48% Increase Over the Past Week: Key Insights

Sep 12 2025NASDAQ.COM

Stocks of MODD, GALT, XCUR, PEPG, and BSGM Surge in After-Hours Trading Following Clinical Developments and Strategic Actions

Sep 12 2025NASDAQ.COM